Aetna modified CPB 0976 covering Ryplazim (plasminogen, human-tvmh) for plasminogen deficiency type 1, effective February 19, 2026. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its coverage policy for Ryplazim under CPB 0976 Aetna system. The policy governs HCPCS code J2998 (injection, plasminogen, human-tvmh, 1 mg) alongside infusion administration codes CPT 96365–96368. This is a specialty biologic with strict medical necessity criteria and mandatory precertification — your billing team needs to know the rules before submitting a single claim.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Plasminogen, Human-tvmh (Ryplazim) |
| Policy Code | CPB 0976 |
| Change Type | Modified |
| Effective Date | February 19, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Ophthalmology, Pulmonology, Infusion Therapy |
| Key Action | Confirm precertification via (866) 752-7021 before billing J2998 for any member |
Aetna Ryplazim Coverage Criteria and Medical Necessity Requirements 2026
The Aetna Ryplazim coverage policy under CPB 0976 covers exactly one diagnosis: plasminogen deficiency type 1 (hypoplasminogenemia), coded as ICD-10-CM E88.02. There are no other covered indications. Every other use is experimental.
To meet medical necessity, members must satisfy both of the following criteria. First, the member must have a baseline plasminogen activity level of 45% or less. Second, the member must have a documented history of lesions and symptoms consistent with plasminogen deficiency type 1.
Aetna spells out acceptable symptom examples: ligneous conjunctivitis, ligneous gingivitis or gingival overgrowth, vision abnormalities, respiratory distress and/or obstruction, and abnormal wound healing. Both criteria must be met — not one or the other. If the chart doesn't document the activity level and the clinical presentation, your claim will not survive review.
The prescribing requirement adds another layer. Ryplazim must be prescribed by or in consultation with a hematologist. A primary care order alone won't satisfy this policy. Make sure the ordering documentation reflects hematology involvement before you submit.
Prior Authorization Requirements for Ryplazim Under Aetna CPB 0976
Prior authorization is mandatory. Aetna requires precertification for all participating providers and members in applicable plan designs. There are no exceptions built into this policy.
Call (866) 752-7021 or fax (888) 267-3277 to initiate precertification. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal. Don't start the infusion series and bill J2998 after the fact — prior auth must come first.
For Medicare patients, this CPB does not apply. Aetna directs Medicare billing to its separate Part B criteria. If you treat Medicare beneficiaries with Ryplazim, confirm coverage through that channel before billing.
Continuation of Therapy Criteria
Aetna's policy addresses continuation explicitly. Ongoing Ryplazim therapy is medically necessary when the member shows benefit from treatment. Benefit means disease stability or improvement.
Acceptable evidence includes improvement in lesion number or size, absence of new lesion development, improved respiratory function, or increased quality of life. Your continuation requests need to document one of these. A chart note that says "patient tolerating medication well" without addressing lesion status or respiratory outcomes is not going to be enough.
Aetna Ryplazim Exclusions and Non-Covered Indications
Aetna's position here is blunt: all indications other than plasminogen deficiency type 1 are considered experimental, investigational, or unproven. There is no list of borderline cases or off-label uses with partial coverage.
This matters for reimbursement because Ryplazim is an ultra-orphan biologic. Clinicians sometimes explore it for other fibrin-related conditions. If a member is billed under anything other than E88.02 with the documented criteria above, expect a claim denial. The policy gives Aetna a clean basis to reject any other diagnosis pairing.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Plasminogen deficiency type 1 (hypoplasminogenemia) — initial therapy | Covered | J2998, E88.02, CPT 96365–96368 | Requires plasminogen activity ≤ 45% AND documented lesion/symptom history; hematologist must prescribe or consult; prior auth required |
| Plasminogen deficiency type 1 — continuation of therapy | Covered | J2998, E88.02, CPT 96365–96368 | Must document disease stability or improvement (lesion count/size, respiratory function, quality of life) |
| All other indications | Not Covered (Experimental/Investigational/Unproven) | — | Aetna considers all off-label uses experimental under CPB 0976 |
Aetna Ryplazim Billing Guidelines and Action Items 2026
The Aetna Ryplazim coverage policy has a narrow target and strict sequencing rules. These action items apply to any practice or infusion center billing J2998 for Aetna commercial members.
| # | Action Item |
|---|---|
| 1 | Confirm precertification before every infusion course. Call (866) 752-7021 before treatment begins. Do not rely on a prior authorization from a previous plan year — this policy was modified February 19, 2026, and prior auths don't carry forward automatically. |
| 2 | Verify the plasminogen activity level is documented in the chart. The threshold is 45% or less. That specific number needs to appear in the lab record or clinical notes. If the ordering physician doesn't have that value documented, the auth request will stall. |
| 3 | Check for hematologist involvement before submitting. The prescribing physician must be a hematologist, or the chart must show a formal consultation. A referral note is not the same as a documented consultation. Audit your intake process so this gets confirmed at scheduling, not after the fact. |
| 4 | Update your charge capture to pair J2998 with ICD-10-CM E88.02. This is the only ICD-10 code covered under this policy. Any other diagnosis code on a claim for J2998 will likely generate a claim denial. Build the E88.02 linkage into your billing templates now. |
| 5 | Bill infusion administration with CPT 96365 for the initial hour. Use CPT 96366 for each additional hour of the same infusion. CPT 96367 and 96368 apply to sequential and concurrent infusions respectively — know which scenario matches the actual administration before you code. These codes require accurate time documentation in the nursing or infusion log. |
| 6 | Structure your continuation auth requests around outcome evidence. Don't submit a generic refill request. Aetna's continuation criteria require documentation of benefit — lesion improvement, absence of new lesions, respiratory improvement, or quality of life change. Pull that evidence from the visit notes before you file. |
| 7 | Separate commercial and Medicare workflows. CPB 0976 applies to commercial plans only. Medicare members need a separate coverage determination. If your practice treats both populations, make sure your prior auth team uses the right pathway for each. |
If your billing team handles a high volume of specialty biologics, this policy follows a familiar pattern — strict diagnosis-specific approval, activity-level thresholds, and continuation criteria tied to functional outcomes. If you're new to Ryplazim billing or unsure how this applies to your payer mix, talk to your compliance officer or billing consultant before the effective date of February 19, 2026 has passed.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Plasminogen, Human-tvmh (Ryplazim) Under CPB 0976
Covered HCPCS Code (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J2998 | HCPCS | Injection, plasminogen, human-tvmh, 1 mg |
J2998 is the primary billing code for Ryplazim. Every unit billed represents 1 mg of the drug. Verify the dose ordered against the units billed — dosing errors here create audit exposure.
Key ICD-10-CM Diagnosis Code
| Code | Description |
|---|---|
| E88.02 | Plasminogen deficiency |
E88.02 is the only diagnosis code that maps to covered status under this policy. Pair it with J2998 on every claim. If your EHR auto-populates a broader metabolic disorder code, override it — the specificity of E88.02 is what satisfies Aetna's medical necessity criteria under CPB 0976.
Get the Full Picture for CPT 96365
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.